Clinical trials

Improving clinical trial label translation through centralized reuse and control

Centralized translation and label approval enabled scalable, compliant clinical label development across global trials, reducing duplication, cost, and timelines.

Challenge

Clinical label translation becomes increasingly complex as trials expand across regions, languages, and regulatory environments. Country-specific requirements drive repeated translation efforts, while multiple studies introduce duplication and variability in label versions across markets.

For a biopharma company managing a growing portfolio of global clinical trials, the absence of a centralized translation framework limited the ability to reuse previously approved content. This fragmented approach increased cost, extended timelines, and introduced risk of inconsistencies that could impact regulatory submissions.

Establishing a scalable translation framework

To address these challenges, a centralized translation and label approval system (ATLAS) was implemented to support consistent, repeatable translation processes across studies.

A structured translation library was established, covering 64 countries, 40 languages, and more than 140 preapproved phrases. This provided a standardized foundation for label development while enabling systematic reuse of validated translations across protocols.

The system also introduced controlled versioning and traceability, allowing updates to be tracked and managed across regions. As new studies were initiated, additional languages could be incorporated without disrupting existing validated content, supporting ongoing reuse and consistency.

Enabling efficiency through reuse and control

By shifting translation from a study-level activity to a centralized, reusable process, the approach reduced redundant translation work and improved consistency across global trials.

As the translation library expanded, efficiencies increased over time, supporting faster turnaround and reducing reliance on repeated regulatory review and translation effort.

At a glance

Program focus
Clinical trial label translation and approval for global studies.

Methods used
Centralized translation and label approval system (ATLAS), reusable translation library, controlled versioning and traceability.

Scope
64 countries, 40 languages, 140+ preapproved phrases.

Key outcome
More than **$523,000** in cost avoidance and 190 business days saved across 2024–2025.

Development impact
Reduced duplication, improved consistency, and established a scalable translation model supporting global trial expansion.

Development impact

Implementation of the centralized translation framework resulted in measurable improvements in both cost and timelines. In 2024, the approach generated more than $260,000 in cost avoidance and reduced timelines by 100 business days. In 2025, continued expansion of the translation library delivered an additional $262,000 in savings and 90 business days saved.

Across the two-year period, this resulted in more than $523,000 in total cost avoidance and 190 business days saved, with efficiencies continuing to compound as reuse increased across programs.

Cost impact of centralized translation approach (2024–2025)